Akero Therapeutics
The Associate Director, Drug Product Development, leads late-stage development activities for EFX within the Technical Operations division, focusing on drug product formulation, manufacturing processes, and regulatory submissions.
Headquarters
South San Francisco, California, United States
Company Size
11-50 employees
Founded
2017
Akero Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformational therapies for metabolic dysfunction‑associated steatohepatitis (MASH) and related metabolic diseases. Their lead investigational candidate, efruxifermin (EFX), is an engineered FGF21‑based therapy designed to improve metabolic health and reduce liver disease in people with MASH. Akero advances programs through clinical development with the goal of addressing underlying metabolic drivers of liver disease and improving long‑term patient outcomes.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Akero Therapeutics.
9% below the average for this role
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
Oct 14, 2025
Director, CMC Product Development – Biologics
Beeline Medicines
Associate Director, Formulation Development
Olema Oncology
Director, Drug Product Development
BioCryst Pharmaceuticals
Associate Director, Drug Product Development & Manufacturing
Entrada Therapeutics
Senior Manager, Regulatory Affairs CMC
Spyre Therapeutics
Biologics Manufacturing Technical Expert III
Gilead Sciences